least common multiple of T and R [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2021-05-26 00:23 (362 d 22:28 ago) – Posting: # 22367
Views: 1,036

Hi Vishal,

» we are designing the fixed dose combination Immediate release test formulation(A+B) […] 325 mg(B) […] Note than RLD (B) available in EU market in 500 mg strength, 325 mg strength not available as RLD.
  1. There are no reference-listed drugs in Europe.
  2. Did you bother reading the section I linked in my previous post? BE means always comparing BA of the same doses. An adjustment$$\small{\frac{f_\textrm{T}}{f_\textrm{R}}=\frac{AUC_\textrm{T}\,\cdot D_\textrm{R}}{AUC_\textrm{R}\,\cdot D_\textrm{T}}}$$would not be acceptable.

Dif-tor heh smusma 🖖 [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,092 posts in 4,630 threads, 1,567 registered users;
online 11 (0 registered, 11 guests [including 6 identified bots]).
Forum time: Monday 22:51 CEST (Europe/Vienna)

There is no adequate defense, except stupidity,
against the impact of a new idea.    Percy Williams Bridgman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5